Rhythm Pharmaceuticals
RYTM
116 hedge funds and large institutions have $1.09B invested in Rhythm Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 42 increasing their positions, 23 reducing their positions, and 38 closing their positions.
1,857% more call options, than puts
Call options by funds: $3.8M | Put options by funds: $194K
83% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 23
10.13% more ownership
Funds ownership: 106.32% → 116.45% (+10%)
1% more capital invested
Capital invested by funds: $1.08B → $1.09B (+$15.7M)
8% less funds holding
Funds holding: 126 → 116 (-10)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
26% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$44.8M |
| 2 |
VA
VR Adviser
New York
|
+$19.7M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$15.2M |
| 4 |
Primecap Management
Pasadena,
California
|
+$12.5M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.9M |
| 2 |
Millennium Management
New York
|
-$9.76M |
| 3 |
Alkeon Capital Management
New York
|
-$5.25M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$5.2M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$4.97M |
RYTM Hedge Fund Activity: Q2 2023 in Review
116 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2023, worth a combined $1.09B — up 1.5% from $1.08B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of RYTM and 28 opened new positions — a net loss of 10 holders — while 23 trimmed existing stakes and 42 added.
The largest buyer was BlackRock, adding an estimated $44.8M. The largest seller was Susquehanna International Group, cutting an estimated $13.9M.
- 116 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2023, down from 126 in Q1 2023.
- Funds reported $1.09B of Rhythm Pharmaceuticals stock for Q2 2023, up 1.5% quarter-over-quarter.
- 28 funds opened new Rhythm Pharmaceuticals positions in Q2 2023 and 38 closed out, a net change of -10 holders.
- The largest Rhythm Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $44.8M added.
- The largest Rhythm Pharmaceuticals seller in Q2 2023 was Susquehanna International Group, an estimated $13.9M sold.
Based on aggregated 13F filings for Q2 2023.